ReviewAntibiotics (Basel, Switzerland)2024
Multidrug-Resistant Sepsis: A Critical Healthcare Challenge.
Review in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07167173 (Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis), which is not on this map. Cited by 85 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis
Who cites it
85 citing papers in PubMed, 4 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- AI-Based Sepsis Prediction in Hospitalized Adults: Systematic Review, Subgroup Meta-Analysis, and Contextual Analysis of Clinical Burden.Journal of medical Internet research · 2026Pooled it
- Antimicrobial resistance in bloodstream infections in West Africa: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Assessing Monoclonal and Polyclonal Antibodies in Sepsis and Septic Shock: A Systematic Review of Efficacy and Safety.International journal of molecular sciences · 2025Pooled it
- Molecular exploration of host-pathogen interactions in severeFrontiers in medicine · 2025Pooled it
- Current and emerging biomaterials for targeted drug delivery in osteomyelitis management.Discover nano · 2026Review
- Assessing Clinical Effectiveness of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam in Bacteremia: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Construction of an associative model for prolonged intensive care unit stay in sepsis patients combined with myocardial injury.Clinics (Sao Paulo, Brazil) · 2026Article
- Genomic Surveillance of ESBL-ProducingPathogens (Basel, Switzerland) · 2026Article
- "Uropathogens and antimicrobial susceptibility patterns in urosepsis patients at kafr el sheikh University hospital: a cross-sectional study".Scientific reports · 2026Article
- Determinants of mortality in carbapenem-resistant Klebsiella pneumoniae ICU Infections: a multivariable clinical and predictive modeling analysis.BMC infectious diseases · 2026Article
- Green Hydrothermal Synthesis of CuO-NPs and CuO-NPs@Alhagi Maurorum for Combating Multidrug Resistant Bacterial Infections.Biological trace element research · 2026Article
- Real-Time Artificial Intelligence for Early Sepsis Prediction Using Dynamic Clinical Data: A Systematic Review.Cureus · 2026Review
- Emergence, evolution, and global dissemination of antimicrobial resistance: A One Health review.Archives of microbiology · 2026Review
- Bacterial Adaptive Responses to Green and Chemically Synthesized Silver Nanoparticles: Implications for Resistance Development.Nanomaterials (Basel, Switzerland) · 2026Article
- Simultaneous measurement of piperacillin, tazobactam and meropenem in patient samples using LC-MS/MS to support β-lactam therapeutic drug monitoring.Analytical methods : advancing methods and applications · 2026Article
- Evaluation of serum progranulin as a biomarker for early detection of neonatal sepsis in a microbiological context.Scientific reports · 2026Article
- Commensal and opportunistic bacteria resistant to fourth-generation cephalosporins or fluoroquinolones isolated from yellow-legged gulls (Larus michahellis) settled in Taranto, Southern Italy.Scientific reports · 2026Article
- Nanostructured Lipid Carriers Enhance Ciprofloxacin Antibacterial Activity Through Diffusion-Controlled Release and Modulation of Bacterial Growth Kinetics.Pharmaceutics · 2026Article
- Re-evaluating cytokine storm syndromes: dysregulated host defense or contextual immune adaptation?European cytokine network · 2026Review
- Antimicrobial-resistance in clinically harmful bacteria contaminating household drinking water in Eastern Uganda highlights urgent need for enhanced antibiotic resistance stewardship.Scientific reports · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis globally accounts for an alarming annual toll of 48.9 million cases, resulting in 11 million deaths, and inflicts an economic burden of approximately USD 38 billion on the United States healthcare system. The rise of multidrug-resistant organisms (MDROs) has elevated the urgency surrounding the management of multidrug-resistant (MDR) sepsis, evolving into a critical global health concern. This review aims to provide a comprehensive overview of the current epidemiology of (MDR) sepsis and its associated healthcare challenges, particularly in critically ill hospitalized patients. Highlighted findings demonstrated the complex nature of (MDR) sepsis pathophysiology and the resulting immune responses, which significantly hinder sepsis treatment. Studies also revealed that aging, antibiotic overuse or abuse, inadequate empiric antibiotic therapy, and underlying comorbidities contribute significantly to recurrent sepsis, thereby leading to septic shock, multi-organ failure, and ultimately immune paralysis, which all contribute to high mortality rates among sepsis patients. Moreover, studies confirmed a correlation between elevated readmission rates and an increased risk of cognitive and organ dysfunction among sepsis patients, amplifying hospital-associated costs. To mitigate the impact of sepsis burden, researchers have directed their efforts towards innovative diagnostic methods like point-of-care testing (POCT) devices for rapid, accurate, and particularly bedside detection of sepsis; however, these methods are currently limited to detecting only a few resistance biomarkers, thus warranting further exploration. Numerous interventions have also been introduced to treat MDR sepsis, including combination therapy with antibiotics from two different classes and precision therapy, which involves personalized treatment strategies tailored to individual needs. Finally, addressing MDR-associated healthcare challenges at regional levels based on local pathogen resistance patterns emerges as a critical strategy for effective sepsis treatment and minimizing adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.